For years, the immune system's power to fight cancer has been harnessed in blood cancers but has met a stubborn wall in solid tumors — tumors that hide, resist, and endure. At the Heidelberg Children's Cancer Center, researchers may have found a crack in that wall: a single infusion of reprogrammed T-cells targeting the PRAME protein brought a 17-year-old with widely metastatic Wilms tumor into complete remission, sustained now for over a year. The case, published in the New England Journal of Medicine in August 2026, does not yet rewrite the standard of care — but it asks, with quiet urgency,
Targeted T-cell therapy achieves complete remission in advanced pediatric solid tumor
A 17-year-old patient with widely metastatic cancer who had exhausted conventional treatment options achieved complete remission through experimental T-cell therapy.
One infusion. One year of sustained remission.
Mark
Why did this work when solid tumors have resisted immunotherapy for so long?
Mimi
The key was specificity. Instead of trying to wake up the immune system generally, they programmed the T-cells to recognize and attack one specific protein—PRAME—that appears on this patient's cancer cells. It's like giving the immune system a photograph instead of a description.
Mark
But couldn't the cancer just stop making that protein and hide?
Mimi
Theoretically, yes. That's why the larger trial matters. One patient, one year—we don't know yet if that's durable or if resistance emerges over time. But the speed of the response here was so complete that it suggests the cancer didn't have time to adapt.
Mark
What's different about this compared to the leukemia treatments that already work?
Mimi
Leukemia cells circulate in the blood, so the immune cells can reach them easily. Solid tumors are dense, walled-off structures. Getting T-cells to penetrate deep into the tumor and survive long enough to do damage has been the real obstacle. This case shows it's possible.
Mark
Is the patient cured, or just in remission?
Mimi
The language is careful: complete remission. More than a year without evidence of disease is significant in pediatric cancer, but one year isn't forever. The PRAMEtime trial will help answer whether this holds up across more patients and longer follow-up.
Mark
Who benefits from this if it works?
Mimi
Children with solid tumors that express PRAME and have exhausted standard treatments. That's a smaller population than you might think, but for those kids, it could be the difference between no options and a real chance.
Der Puls
- A teenager with cancer in the brain, lungs, liver, and abdomen had exhausted every conventional option — the disease was still advancing.
- Within nine days of a single T-cell infusion, biopsies revealed the tumor was being overwhelmed from within, with cancer cells dying en masse.
- By three months, no living cancer cells could be found; more than a year later, the patient remains in complete remission with no signs of relapse.
- The result cracks open one of pediatric oncology's most stubborn problems — solid tumors have long resisted the immunotherapies that transformed leukemia treatment.
- Researchers are now planning the PRAMEtime clinical trial for 2027 to determine whether this outcome can be replicated and scaled across a broader patient population.
For years, the immune system's power to fight cancer has been harnessed in blood cancers but has met a stubborn wall in solid tumors — tumors that hide, resist, and endure. At the Heidelberg Children's Cancer Center, researchers may have found a crack in that wall: a single infusion of reprogrammed T-cells targeting the PRAME protein brought a 17-year-old with widely metastatic Wilms tumor into complete remission, sustained now for over a year. The case, published in the New England Journal of Medicine in August 2026, does not yet rewrite the standard of care — but it asks, with quiet urgency, whether it should.
A 17-year-old with Wilms tumor — spread to the brain, lungs, liver, and abdomen — had run out of options. Conventional treatments had failed, and the disease was still moving. Researchers at the Heidelberg Children's Cancer Center in Germany then attempted something that had never succeeded in solid tumors: they extracted the patient's own T-cells, reprogrammed them to recognize a protein called PRAME found on cancer cells, and returned them in a single infusion.
Nine days later, a biopsy revealed the T-cells had flooded the tumor and were destroying it. At three months, no living cancer cells remained. More than a year after that one injection, the patient is still cancer-free — no relapse, no evidence of disease on imaging.
The case, published in the New England Journal of Medicine in August 2026, carries weight beyond one patient's survival. Cell-based immunotherapies have already transformed outcomes in childhood leukemias, but solid tumors have resisted them — harder to penetrate, better at evading immune detection. This result suggests that resistance may not be permanent.
What makes the outcome especially striking is its directness: one infusion, one patient, one year of sustained remission. The modified T-cells found their target and eliminated it — no partial response, no eventual regrowth. The cancer simply receded.
The next question is whether this can be repeated. A larger clinical trial called PRAMEtime is planned for 2027 to test whether the approach holds across more patients. That trial will determine whether this teenager's outcome marks the beginning of something new — or remains, for now, a singular and extraordinary exception.
A 17-year-old patient with Wilms tumor—a cancer that had spread to the brain, lungs, liver, and abdomen—had run out of options. Conventional treatments had failed. The disease was advancing. Then researchers at the Heidelberg Children's Cancer Center in Germany tried something that had never worked before in solid tumors: they took the patient's own T-cells, reprogrammed them to hunt a specific protein called PRAME that appears on cancer cells, and infused a single dose back into the body.
Nine days later, a biopsy showed what the doctors were hoping to see: massive numbers of T-cells had invaded the tumor, and the cancer cells were dying in large numbers. At three months, there were no living cancer cells left to find. More than a year after that single injection, the patient remained cancer-free—no signs of disease on imaging, no evidence of relapse.
The case, published in the New England Journal of Medicine in August 2026, matters because it breaks open a problem that has haunted pediatric oncology for years. Cell-based immunotherapies—treatments that reprogram a patient's own immune system to fight cancer—have transformed outcomes in childhood leukemias. But solid tumors have been different. They're harder to penetrate. They hide from the immune system. They've resisted the approaches that worked elsewhere. This teenager's complete remission suggests that barrier may not be as fixed as everyone thought.
What makes the result striking is its simplicity and speed. One infusion. One patient. One year of sustained remission. The mechanism is straightforward: the modified T-cells found their target, invaded the tumor, and killed it. There was no gradual response, no partial shrinkage followed by regrowth. The cancer receded completely.
The breakthrough has already prompted the next step. Researchers are planning a larger clinical trial called PRAMEtime, scheduled to begin in 2027, to see whether this approach can work in more patients and whether it can be refined further. That trial will be the real test—whether one remarkable case points toward a new standard of care or remains an outlier.
For now, the case stands as proof that even very aggressive solid tumors in children can be forced into complete remission through targeted immunotherapy. It's a reminder that the tools exist; the question is how to use them, and how widely. The next phase of research will tell whether this teenager's outcome becomes a template or remains a singular victory.
Bemerkenswerte Zitate
Cellular immunotherapies have revolutionized pediatric leukemias, but their application to solid tumors has encountered major obstacles. This success proves that targeted immunotherapy can force even very aggressive solid tumors to completely recede.— Loizos G. Loizou, Head of Cyprus International Action Plan for Children with Cancer at ELPIDA Foundation
Möchten Sie die ganze Geschichte?
Das Original lesen bei Oncodaily ↗
Health & Medicine